
-
Clearside Biomedical NasdaqGM:CLSD Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Location: 900 North Point Parkway, Alpharetta, GA, 30005, United States | Website: https://clearsidebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
101M
Cash
13.63M
Avg Qtr Burn
-5.669M
Short % of Float
0.33%
Insider Ownership
13.02%
Institutional Own.
14.32%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XIPERE (CLS-TA) Details Macular edema | Approved Quarterly sales | |
belzupacap saratalocan (bel-sar) (AU-011) Details Primary Choroidal Melanoma, Cancer | Phase 3 Data readout | |
CLS-AX Details Wet age-related macular degeneration , Age-related macular degeneration | Phase 2b Data readout | |
RGX-314 Details Wet age-related macular degeneration , Age-related macular degeneration | Phase 2 Update | |
ABBV-RGX-314 Details Diabetic retinopathy , Diabetic macular edema | Phase 2 Update |